

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1653HXP

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* Welcome to STN International \* \* \* \* \*

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	AUG 10	Time limit for inactive STN sessions doubles to 40 minutes
NEWS	3	AUG 18	COMPENDEX indexing changed for the Corporate Source (CS) field
NEWS	4	AUG 24	ENCOMPLIT/ENCOMPLIT2 reloaded and enhanced
NEWS	5	AUG 24	CA/CAPplus enhanced with legal status information for U.S. patents
NEWS	6	SEP 09	50 Millionth Unique Chemical Substance Recorded in CAS REGISTRY
NEWS	7	SEP 11	WPIDS, WPINDEX, and WPIX now include Japanese FTERM thesaurus
NEWS	8	OCT 21	Derwent World Patents Index Coverage of Indian and Taiwanese Content Expanded
NEWS	9	OCT 21	Derwent World Patents Index enhanced with human translated claims for Chinese Applications and Utility Models
NEWS	10	NOV 23	Addition of SCAN format to selected STN databases
NEWS	11	NOV 23	Annual Reload of IFI Databases
NEWS	12	DEC 01	FRFULL Content and Search Enhancements
NEWS	13	DEC 01	DGENE, USGENE, and PCTGEN: new percent identity feature for sorting BLAST answer sets
NEWS	14	DEC 02	Derwent World Patent Index: Japanese FI-TERM thesaurus added
NEWS	15	DEC 02	PCTGEN enhanced with patent family and legal status display data from INPADOCDB
NEWS	16	DEC 02	USGENE: Enhanced coverage of bibliographic and sequence information

NEWS EXPRESS MAY 26 09 CURRENT WINDOWS VERSION IS V8.4,  
AND CURRENT DISCOVER FILE IS DATED 06 APRIL 2009.

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS LOGIN Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

\* \* \* \* \* STN Columbus \* \* \* \* \*

FILE 'HOME' ENTERED AT 19:57:08 ON 19 DEC 2009

=> file medline, uspatful, embase, wpids, biosis, hcaplus, scisearch, biotechds  
COST IN U.S. DOLLARS                      SINCE FILE              TOTAL  
                                         ENTRY              SESSION  
FULL ESTIMATED COST                      0.22              0.22

FILE 'MEDLINE' ENTERED AT 19:57:52 ON 19 DEC 2009

FILE 'USPATFULL' ENTERED AT 19:57:52 ON 19 DEC 2009  
CA INDEXING COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EMBASE' ENTERED AT 19:57:52 ON 19 DEC 2009  
Copyright (c) 2009 Elsevier B.V. All rights reserved.

FILE 'WPIDS' ENTERED AT 19:57:52 ON 19 DEC 2009  
COPYRIGHT (C) 2009 THOMSON REUTERS

FILE 'BIOSIS' ENTERED AT 19:57:52 ON 19 DEC 2009  
Copyright (c) 2009 The Thomson Corporation

FILE 'HCAPLUS' ENTERED AT 19:57:52 ON 19 DEC 2009  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2009 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'SCISEARCH' ENTERED AT 19:57:52 ON 19 DEC 2009  
Copyright (c) 2009 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 19:57:52 ON 19 DEC 2009  
COPYRIGHT (C) 2009 THOMSON REUTERS

=> s inflammatory bowel disease  
L1            126927 INFLAMMATORY BOWEL DISEASE

=> s ulcerative colitis  
L2            136270 ULCERATIVE COLITIS

=> s l1 and treatment  
L3            54174 L1 AND TREATMENT

=> s l2 and treatment  
L4            55828 L2 AND TREATMENT

=> s l4 and l2  
L5            55828 L4 AND L2

=> s l5 and (ferritin)  
L6            601 L5 AND (FERRITIN)

=> s l6 and (iron dextran)  
L7            279 L6 AND (IRON DEXTRAN)

=> s l7 and (desferoxamine)  
L8            4 L7 AND (DESFEROXAMINE)

=>

=> d l8 ti abs ibib tot

L8 ANSWER 1 OF 4 USPATFULL on STN  
TI PHARMACEUTICAL USE OF NITRIC OXIDE, HEME OXYGENASE-1 AND PRODUCTS OF  
HEME DEGRADATION  
AB The present invention relates to the treatment of disorders  
using nitric oxide (NO), heme oxygenase-1 (HO-1) and heme degradation  
products such as carbon monoxide (CO), biliverdin, bilirubin and iron.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2008:195368 USPATFULL  
TITLE: PHARMACEUTICAL USE OF NITRIC OXIDE, HEME OXYGENASE-1  
AND PRODUCTS OF HEME DEGRADATION  
INVENTOR(S): Bach, Fritz H., Manchester-by-the-sea, MA, UNITED  
STATES  
Otterbein, Leo E., New Kensington, PA, UNITED STATES  
PATENT ASSIGNEE(S): Beth Israel Deaconess Medical Center, Inc., Boston, MA,  
UNITED STATES (U.S. corporation)  
University of Pittsburgh of the Commonwealth System of  
Higher Education, Pittsburgh, PA, UNITED STATES (U.S.  
corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20080171021	A1	20080717
APPLICATION INFO.:	US 2007-931645	A1	20071031 (11)
RELATED APPLN. INFO.:	Division of Ser. No. US 2003-600182, filed on 20 Jun 2003, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-390457P	20020621 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, P.O. BOX 1022, MINNEAPOLIS, MN, 55440-1022, US	
NUMBER OF CLAIMS:	3	
EXEMPLARY CLAIM:	1-15	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	2123	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L8 ANSWER 2 OF 4 USPATFULL on STN  
TI Spinner preparation machine and cavity resonator  
AB The present invention relates to the treatment of disorders  
using heme oxygenase-1 and heme degradation products.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2006:4464 USPATFULL  
TITLE: Spinner preparation machine and cavity resonator  
INVENTOR(S): Bach, Fritz H., Manchester-by-the-sea, MA, UNITED  
STATES  
Berberat, Pascal O., Heidelberg, GERMANY, FEDERAL  
REPUBLIC OF  
Robson, Simon C., Weston, MA, UNITED STATES

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 20060003922	A1	20060105
APPLICATION INFO.:	US 2003-511612	A1	20030415 (10)
	WO 2003-US11411		20030415
			20050805 PCT 371 date

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2002-372762P	20020415 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, P.O. BOX 1022, MINNEAPOLIS, MN, 55440-1022, US	
NUMBER OF CLAIMS:	58	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	27 Drawing Page(s)	
LINE COUNT:	3083	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 3 OF 4 USPATFULL on STN

TI Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation

AB The present invention relates to the treatment of disorders using nitric oxide (NO), heme oxygenase-1 (HO-1) and heme degradation products such as carbon monoxide (CO), biliverdin, bilirubin and iron.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

ACCESSION NUMBER: 2004:171542 USPATFULL

TITLE: Pharmaceutical use of nitric oxide, heme oxygenase-1 and products of heme degradation

INVENTOR(S): Bach, Fritz H., Manchester-by-the-sea, MA, UNITED STATES  
Otterbein, Leo E., New Kensington, PA, UNITED STATES

	NUMBER	KIND	DATE
	-----	-----	-----
PATENT INFORMATION:	US 20040131703	A1	20040708
APPLICATION INFO.:	US 2003-600182	A1	20030620 (10)

	NUMBER	DATE
	-----	-----
PRIORITY INFORMATION:	US 2002-390457P	20020621 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	FISH & RICHARDSON PC, 225 FRANKLIN ST, BOSTON, MA, 02110	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	2300	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		

L8 ANSWER 4 OF 4 WPIDS COPYRIGHT 2009 THOMSON REUTERS on STN

TI Use of heme oxygenase-1 and heme degradation products for e.g. reducing inflammation, organ transplantation and treating e.g. cellular proliferative disorder

AN 2003-903222 [82] WPIDS

AB WO 2003088748 A1 UPAB: 20060121

NOVELTY - Reducing (M1) inflammation involves:

(1) administration of at least one treatment selected from inducing ferritin;

(2) expressing ferritin; and

(3) administering a pharmaceutical composition (C1) comprising heme oxygenase-1 (HO-1), bilirubin, biliverdin, ferritin, iron, desferoxamine, salicylaldehyde isonicotinoyl hydrazone, iron dextran, or apoferritin.

DETAILED DESCRIPTION - INDEPENDENT CLAIMS are also included for:

(1) A method (M2) of transplanting an organ by three different ways (M2a, M2b, M2c). (M2a) involves (ia) administration of at least one of the treatments to a donor to enhance survival or function of the organ after the transplantation, (ib) obtaining an organ from the donor, and (ic) transplanting the organ into a recipient. (M2b) involves (iia) administering to an organ of a donor ex vivo at least one of the treatments, and (iib) transplanting the organ into a recipient. (M2c) involves (iia) transplanting an organ from a donor into a recipient, and (iib) administering at least one of the treatments to the recipient; and

(2) A method (M3) of performing angioplasty and vascular surgery involving performing angioplasty and vascular surgery, respectively, and administering at least one of the treatments.

ACTIVITY - Anti-inflammatory; Antiulcer; Antiasthmatic; Tranquilizer; Respiratory-Gen.; Thrombolytic; Hypotensive; Cardiovascular Gen.; Cerebroprotective; Antiarteriosclerotic; Vasotropic; Cardiant; Nephrotropic; Hepatotropic; Virucide; Gastrointestinal Gen.; Antirheumatic; Antiarthritic; Vulnerary; Neuroprotective; Nootropic; Antiparkinsonian; Immunosuppressive; Antibacterial; Uropathic; Cytostatic; Gynecological.

The anti-inflammatory efficacy of biliverdin was evaluated in an animal model of endotoxic shock. Administration of endotoxin in male Sprague-Dawley rats resulted in lung inflammation, neutrophil accumulation, and increased levels of tumor necrosis factor-alpha (TNF-alpha) in the serum. The rats were administered with biliverdin (50 micromol/kg) 17 hours prior to, and 8 hours after endotoxin administration. Serum level of TNF-alpha was measured by ELISA kits, and total cell counts was determined by differential analysis. The results showed that biliverdin reduced levels of TNF-alpha; levels of neutrophils and protein accumulation in the airspace; and also increased the levels of anti-inflammatory cytokine IL-10.

MECHANISM OF ACTION - None given.

USE - The treatment is useful for reducing and treating inflammation of the heart, lung, liver, spleen, brain skin and kidney; inflammatory condition (e.g. amoebic dysentery, bacillary dysentery, schistosomiasis, campylobacter enterocolitis, yersinia enterocolitis, enterobius vermicularis, radiation enterocolitis, ischaemic colitis, eosinophilic gastroenteritis, ulcerative colitis, indeterminate colitis, and Crohn's disease) localized in the gastrointestinal tract); asthma; adult respiratory distress syndrome; interstitial pulmonary fibrosis; pulmonary emboli; chronic obstructive pulmonary disease; primary pulmonary hypertension; chronic pulmonary emphysema; congestive heart failure; peripheral vascular disease; stroke; atherosclerosis; ischemia-reperfusion injury; heart attacks; glomerulonephritis; nephrotic disorders; infection of the genitourinary tract; viral and toxic hepatitis; cirrhosis; ileus; necrotizing enterocolitis; specific and non-specific inflammatory bowel disease; rheumatoid arthritis, deficient wound healing, Alzheimer's disease, Parkinson's disease, graft versus host disease, and hemorrhagic, septic, or anaphylactic shock; cellular proliferative and differentiative disorder. For reducing the effects of ischemia. For transplanting organs and performing angioplasty or vascular surgery (all claimed). Also for treating other autoimmune diseases and reproductive disorders.

ADVANTAGE - The heme-oxygenase-1 and the heme degradation products attenuate inflammation and suppress the damage associated with ischemia.

ACCESSION NUMBER: 2003-903222 [82] WPIDS  
TITLE: Use of heme oxygenase-1 and heme degradation products for e.g. reducing inflammation, organ transplantation and treating e.g. cellular proliferative disorder  
DERWENT CLASS: B04; B05; S03  
INVENTOR: BACH F H; BERBERAT P O; ROBSON S C

PATENT ASSIGNEE: (BACH-I) BACH F H; (BERB-I) BERBERAT P O; (ROBS-I) ROBSON  
S C; (BEIS-C) BETH ISRAEL DEACONESS MEDICAL CENT  
COUNTRY COUNT: 102

PATENT INFO ABBR.:

PATENT NO	KIND	DATE	WEEK	LA	PG	MAIN IPC
WO 2003088748	A1	20031030	(200382)*	EN	56	[27]
AU 2003226366	A1	20031103	(200438)	EN		
EP 1499186	A1	20050126	(200508)	EN		
JP 2005522521	W	20050728	(200549)	JA	59	
US 20060003922	A1	20060105	(200603)	EN		

APPLICATION DETAILS:

PATENT NO	KIND	APPLICATION	DATE
WO 2003088748	A1	WO 2003-US11411	20030415
AU 2003226366	A1	AU 2003-226366	20030415
EP 1499186	A1	EP 2003-746978	20030415
JP 2005522521	W	JP 2003-585506	20030415
EP 1499186	A1	WO 2003-US11411	20030415
JP 2005522521	W	WO 2003-US11411	20030415
US 20060003922	A1 Provisional	US 2002-372762P	20020415
US 20060003922	A1	WO 2003-US11411	20030415
US 20060003922	A1	US 2005-511612	20050805

FILING DETAILS:

PATENT NO	KIND	PATENT NO
AU 2003226366	A1 Based on	WO 2003088748 A
EP 1499186	A1 Based on	WO 2003088748 A
JP 2005522521	W Based on	WO 2003088748 A

PRIORITY APPLN. INFO: US 2002-372762P 20020415  
US 2005-511612 20050805

=>